Natera Secures 30% Ongoing Royalty in MRD Patent Victory

Natera (NTRA) announced on Thursday that the United States District Court for the District of Delaware has ruled in its favor regarding a long-standing patent dispute. The court has ordered an ongoing 30% royalty on certain post-injunction sales, marking a substantial legal win for the company. The litigation involved competitors ArcherDx and Invitae, focusing on the intellectual property surrounding Minimal Residual Disease (MRD) testing. MRD tests are critical tools used in oncology to monitor for the recurrence of cancer, making the associated patent rights highly valuable in the diagnostics space. The 30% royalty rate is particularly notable due to its magnitude, ensuring a continuous revenue stream for Natera from the sales of the contested technologies by the opposing parties. This financial arrangement provides a predictable lift to the company's top line. From a market perspective, this ruling strengthens Natera's competitive position and validates its intellectual property portfolio. By securing these royalties, Natera not only gains a financial advantage but also establishes a stronger legal precedent to protect its proprietary testing methods against future infringement.